7.39
Alpha Tau Medical Ltd stock is traded at $7.39, with a volume of 755.86K.
It is down -1.86% in the last 24 hours and up +6.79% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$7.53
Open:
$7.76
24h Volume:
755.86K
Relative Volume:
2.33
Market Cap:
$650.39M
Revenue:
-
Net Income/Loss:
$-42.63M
P/E Ratio:
-13.99
EPS:
-0.5281
Net Cash Flow:
$-39.43M
1W Performance:
+1.23%
1M Performance:
+6.79%
6M Performance:
+86.62%
1Y Performance:
+184.23%
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DRTS
Alpha Tau Medical Ltd
|
7.39 | 662.71M | 0 | -42.63M | -39.43M | -0.5281 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau to Present Alpha DaRT–Pembrolizumab Head and Neck Cancer Data at AHNS 2026 - TipRanks
Alpha Tau abstract on cancer therapy accepted for presentation By Investing.com - Investing.com Canada
Elderly head and neck cancer study gets AHNS podium slot - Stock Titan
Alpha Tau (DRTS) wins AHNS podium slot for Alpha DaRT and pembrolizumab head and neck cancer study - Stock Titan
Alpha Tau pancreatic data: 19 of 19 controlled, 8 device events - Stock Titan
Alpha Tau reports disease control in pancreatic cancer trial By Investing.com - Investing.com Australia
Alpha Tau reports disease control in pancreatic cancer trial - Investing.com
Alpha Tau Reports 100% Local Disease Control in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026 - TipRanks
Alpha Tau Announces 100% Local Disease Control Rate and - GlobeNewswire
[EFFECT] Alpha Tau Medical Ltd. SEC Filing - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Reaches New 1-Year HighTime to Buy? - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Trading Up 13.6%Here's What Happened - MarketBeat
Alpha Tau Medical (NASDAQ: DRTS) files $300M shelf; $100M ATM pact - Stock Titan
Alpha Tau to Present Pooled Pancreatic Cancer Alpha DaRT Data at 2026 ASCO Meeting - TipRanks
Alpha Tau abstract accepted at ASCO annual meeting in May - Investing.com
Alpha Tau abstract accepted at ASCO annual meeting in May By Investing.com - Investing.com Canada
Alpha Tau Announces Presentation of Pancreatic Cancer Data - GlobeNewswire
Alpha Tau (Nasdaq: DRTS) ASCO abstract pools 58 pancreatic cancer patients - Stock Titan
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval - Investing.com
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval By Investing.com - Investing.com South Africa
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Alpha Tau Wins FDA Clearance To Expand Alpha DaRT Pancreatic Cancer Trial - RTTNews
Alpha Tau Treats First European Pancreatic Cancer Patient With Alpha DaRT in ACAPELLA Trial - TipRanks
Alpha Tau (NASDAQ: DRTS) advances Alpha DaRT pancreatic cancer clinical trials - Stock Titan
Alpha Tau expands pancreatic cancer trial to 40, adds second chemo - Stock Titan
Alpha Tau Successfully Treats First Pancreatic Cancer - GlobeNewswire
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Alpha Tau Medical (DRTS) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
Alpha Tau Medical (DRTS) Investor presentation Summary - Quartr
Alpha Tau Medical (DRTS) 2nd Annual Lytham Partners Healthcare Investor Summit summary - Quartr
Is Alpha Tau (DRTS) stock trading at a discount | Q4 2025: Profit Exceeds ViewsPopular Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
DRTS (Alpha Tau Medical Ltd. Ordinary Shares) posts narrower Q4 2025 loss than estimates, shares rise 0.75 percent today.GDR - Cổng thông tin điện tử tỉnh Lào Cai
S Morry Blumenfeld Net Worth (2026) - GuruFocus
Alan Adler Net Worth (2026) - GuruFocus
Maya Netser Net Worth (2026) - GuruFocus
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY) - The Globe and Mail
Michael Avruch Net Worth (2026) - GuruFocus
Uzi Sofer Net Worth (2026) - GuruFocus
Raphi Levy Net Worth (2026) - GuruFocus
Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Exploring a 20.56% Potential Upside in Biotechnology - DirectorsTalk Interviews
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
DRTS Options Volatility — NASDAQ:DRTS - TradingView
DRTS Options Chain — NASDAQ:DRTS - TradingView
Shorts Report: Will Alpha Tau Medical Ltd Equity Warrant stock benefit from M A2026 Earnings Surprises & High Return Trade Guides - baoquankhu1.vn
Growth Recap: Will Alpha Tau Medical Ltd Equity Warrant benefit from rising consumer demandQuarterly Trade Review & High Conviction Investment Ideas - baoquankhu1.vn
Jobs Data: Can Alpha Tau Medical Ltd continue delivering strong returnsEarnings Overview Summary & Safe Capital Preservation Plans - baoquankhu1.vn
ETFs Investing in Alpha Tau Medical Ltd Stocks - TradingView
Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS - MarketBeat
FOMO Trade: Will Alpha Tau Medical Ltd Equity Warrant stock benefit from M A2026 Geopolitical Influence & AI Based Trade Execution Alerts - baoquankhu1.vn
Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS - MarketBeat
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):